Autonomix Medical, INC 8-K filings

Autonomix Medical, Inc. disclosed a cash balance of approximately $5.1 million as of July 28, 2026, with 971,043 shares of common stock outstanding.

Autonomix Medical announced a warrant inducement agreement to exercise existing warrants, raising approximately $2.6 million and issuing new warrants.

Autonomix Medical, Inc. announced it has regained compliance with Nasdaq's minimum $1.00 bid price requirement, closing the deficiency matter.

Autonomix Medical is consolidating its common stock through a 1-for-21 reverse split effective June 24, 2026, to restructure its equity and maintain market compliance.

Autonomix Medical, Inc. received a deficiency letter from Nasdaq for failing to maintain the minimum $1.00 bid price requirement for its common stock.

Autonomix Medical, Inc. announced new subgroup clinical data from its PoC study demonstrating rapid, durable, and meaningful pain relief in pancreatic cancer patients across all disease stages.

Autonomix Medical, Inc. completed a private placement raising approximately $5.0 million through the sale of pre-funded and Series C common stock warrants to an institutional investor.

Autonomix Medical, Inc. stockholders approved all proposals at its annual meeting, including a reverse stock split authority, an amended equity incentive plan, and a significant stock issuance.

Autonomix Medical, Inc. announced an increase of $1.4 million to its 'At Market Issuances Sales Agreement,' allowing for the sale of additional common stock.

Autonomix Medical, Inc. entered a purchase agreement with Lincoln Park Capital Fund, LLC for up to $15 million in common stock over 24 months.

Autonomix Medical, Inc. has entered into agreements with warrant holders to induce the exercise of existing warrants, generating approximately $2.5 million in gross proceeds and issuing new Series B warrants.

Autonomix Medical reports positive outcomes from its first-in-human proof-of-concept trial for pancreatic cancer pain treatment and initiates a market expansion study for visceral cancer pain.

Autonomix Medical, Inc. announced an At Market Issuance Sales Agreement to potentially raise up to $2.1 million for working capital and general corporate purposes.

Autonomix Medical announced its Q3 fiscal year 2025 financial results, highlighting progress in clinical trials, intellectual property expansion, and regulatory preparations.

Autonomix Medical's CEO, Brad Hauser, participated in the Virtual Investor Closing Bell Series on January 22, 2025, with a webcast replay available for 90 days.

Autonomix Medical successfully closed a public offering, raising $10 million to fund clinical trials and research.

Autonomix Medical announced promising preliminary results from its clinical trial for pancreatic cancer pain, showing significant pain reduction and complete opioid cessation in a lead-in patient group, alongside its second quarter fiscal year 2025 financial results.

Autonomix Medical is investigating a discrepancy in the number of shares requested by DTCC following a one-for-twenty reverse stock split.

Autonomix Medical has announced a 1-for-20 reverse stock split, effective October 24, 2024, to consolidate its shares and maintain its Nasdaq listing.

Autonomix Medical successfully held its annual meeting, electing all director nominees and approving a reverse stock split authorization.

Autonomix Medical has received a notice from Nasdaq regarding its failure to maintain a minimum share price of $1.00, placing it at risk of delisting.

Autonomix Medical announced positive early results from its pancreatic cancer pain trial and reported a net loss of $2.7 million for the first quarter of fiscal year 2025.

Autonomix Medical has secured a license for RF Innovations' Apex 6 Radiofrequency Generator, an FDA-cleared ablation technology, to enhance its therapeutic development.

Autonomix Medical's Compensation Committee has approved salary adjustments, cash bonuses, and stock option grants for key executives.

Autonomix Medical reports positive preliminary results from its human clinical trial, showing significant pain reduction in pancreatic cancer patients using transvascular radiofrequency ablation.

Autonomix Medical has appointed Brad Hauser as its new CEO, while former CEO Lori Bisson will transition to Executive Vice Chair, effective immediately.

Autonomix Medical announced its full year 2024 financial results, highlighting progress in clinical trials and technology development, including a focus on pancreatic cancer pain treatment.

Autonomix Medical is developing a novel catheter-based technology with 3,000 times greater sensitivity than current methods to target and treat nerves, initially focusing on pancreatic cancer pain.

Autonomix Medical successfully closed its initial public offering (IPO) raising $11.2 million and regained exclusive worldwide rights to its cardiology technology for $8 million.